U.S. market Closed. Opens in 4 hours 27 minutes

BEAM | Beam Therapeutics Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 24.39 - 25.87
52 Week Range 20.84 - 49.50
Beta 2.07
Implied Volatility 85.01%
IV Rank 77.24%
Day's Volume 912,776
Average Volume 945,546
Shares Outstanding 82,805,600
Market Cap 2,027,909,144
Sector Healthcare
Industry Biotechnology
IPO Date 2020-02-06
Valuation
Profitability
Growth
Health
P/E Ratio -15.50
Forward P/E Ratio N/A
EPS -1.58
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 461
Country USA
Website BEAM
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
BEAM's peers: ADPT, ALLO, ARCT, EDIT, CRSP, CRBU, VERV, NTLA, FATE, PRME, VRTX, DNA, SANA, CGC, CGEN, MRNA, NAUT, QSI, TXG, UBX
*Chart delayed
Analyzing fundamentals for BEAM we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is weak. For more detailed analysis please see BEAM Fundamentals page.

Watching at BEAM technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, but short-term trend is bullish. More technicals details can be found on BEAM Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙